Is DARA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

862 people get DARA articles and Market Currents by email alert.

Get email alerts on DARA »

HEADLINES:

DARA Reports First Quarter 2013 Financial Results and Operational Highlights

Marketwire (May 15, 2013)
DARA and HELSINN Announce U.S. Launch of Gelclair(R), an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis

Marketwire (Apr 22, 2013)
Dara Biosciences: Don't Believe The Hype Surrounding This Biopharma
EnhydrisPECorp • Thu, Apr 11 • 39 Comments
DARA Bio: A Vastly Undervalued Emerging Story
PropThink • Wed, Apr 10 • 9 Comments
DARA BioSciences Enters Into Distribution Agreement for Gelclair(R) and Soltamox(R) With Prime Therapeutics Specialty Pharmacy

Marketwire (Apr 3, 2013)
The Week Ahead Could Be Pivotal For These Small-Cap Companies' Stocks
Chemistfrog • Tue, Apr 2 • 7 Comments
DARA Reports Year-End 2012 Financial Results

Marketwire (Apr 1, 2013)
Nuvilex: A Penny Stock That Could Be A Disease-Fighting Game Changer
Stone Street Advisors • Fri, Mar 22 • 14 Comments
DARA BioSciences to Present at 25th Annual ROTH Conference

Marketwire (Mar 18, 2013)
Biotech Stocks With Recent Developments: 3 To Consider, 1 To Avoid
Brian L. Wilson • Wed, Mar 6 • 9 Comments
DARA BioSciences Appoints Haywood Cochrane Jr. as Chairman of the Board of Directors and Names Paul Richardson as a New Board Member

Marketwire (Mar 1, 2013)
Upcoming Catalysts For These BioPharmas Provide Potential Upside
Scott Matusow • Wed, Feb 20 • 20 Comments
DARA BioSciences Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule

Business Wire (Feb 14, 2013)
DARA BioSciences to Present at 15th Annual BIO CEO & Investor Conference

Business Wire (Feb 11, 2013)
Dara BioSciences: A Catalyst Primer
Jordan Pease • Tue, Feb 5 • 10 Comments
Imminent Catalysts Should Keep Investor Interest Alive For Dara BioSciences
Chemistfrog • Tue, Feb 5 • 2 Comments
Meetings With Management: JPM Healthcare And The Biotech Showcase
PropThink • Fri, Jan 11 • 19 Comments
DARA BioSciences to Present at the 6th Annual OneMedForum Conference

Business Wire (Jan 8, 2013)
DARA BioSciences to Raise $2.8 Million Pursuant to Securities Purchase Agreement

Business Wire (Dec 31, 2012)
DARA Biosciences Seeks Orphan Drug Status For KRN5500
Brian L. Wilson • Tue, Dec 4, 2012 • 3 Comments

To learn more about Seeking Alpha Pro, click here.

Dara Biosciences: Don't Believe The Hype Surrounding This Biopharma
EnhydrisPECorp • Thu, Apr 11 • 39 Comments
DARA Bio: A Vastly Undervalued Emerging Story
PropThink • Wed, Apr 10 • 9 Comments
Dara BioSciences: A Catalyst Primer
Jordan Pease • Tue, Feb 5 • 10 Comments
Imminent Catalysts Should Keep Investor Interest Alive For Dara BioSciences
Chemistfrog • Tue, Feb 5 • 2 Comments
DARA Biosciences Seeks Orphan Drug Status For KRN5500
Brian L. Wilson • Tue, Dec 4, 2012 • 3 Comments
Dara: The Future Of Oncology BioPharma On The Cheap
Stone Street Advisors • Mon, Dec 3, 2012 • 13 Comments
Orphan Drug Status Potentially Huge For DARA Bio
PropThink • Thu, Nov 29, 2012 • 4 Comments
Time To Buy DARA Bio
Jason Napodano • Fri, Sep 14, 2012 • 44 Comments

The Week Ahead Could Be Pivotal For These Small-Cap Companies' Stocks
Chemistfrog • Tue, Apr 2 • 7 Comments
Nuvilex: A Penny Stock That Could Be A Disease-Fighting Game Changer
Stone Street Advisors • Fri, Mar 22 • 14 Comments
Biotech Stocks With Recent Developments: 3 To Consider, 1 To Avoid
Brian L. Wilson • Wed, Mar 6 • 9 Comments
Upcoming Catalysts For These BioPharmas Provide Potential Upside
Scott Matusow • Wed, Feb 20 • 20 Comments
Meetings With Management: JPM Healthcare And The Biotech Showcase
PropThink • Fri, Jan 11 • 19 Comments
3 Best Biotech Stocks For This Week (Part II)
Jorge Aura • Mon, Sep 17, 2012 • 11 Comments
4 Healthcare Companies With Insider Buys This Week
Markus Aarnio • Fri, Jul 27, 2012 • 2 Comments
Stocks Lose on Economic, Banking Worries
Midnight Trader • Thu, Aug 18, 2011 • 1 Comment
Pharma Visionary, Dara Bioscience's Franco: Big Pharma Is Interested in Us
M. E. Garza • Thu, Feb 3, 2011 • 1 Comment
Life Sciences Companies Raise Record Amounts of Capital
The Burrill Report • Fri, Dec 31, 2010
China Analyst: 10 Pharma Stocks With Highest Growth Potential
Douglas Cress • Fri, Oct 8, 2010 • 7 Comments
Closing Update for Tuesday, July 14
Midnight Trader • Tue, Jul 14, 2009
Biotech Day In Review: Amgen Hit with SEC Investigation
Centient Biotech Investor • Thu, Mar 1, 2007
Biotech Stocks Day-in-Review: Genentech Closes Third Deal This Week
Centient Biotech Investor • Sun, Jan 14, 2007

There are no Transcripts on DARA.

DARA Reports First Quarter 2013 Financial Results and Operational Highlights

Marketwire (May 15, 2013)
DARA and HELSINN Announce U.S. Launch of Gelclair(R), an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis

Marketwire (Apr 22, 2013)
DARA BioSciences Enters Into Distribution Agreement for Gelclair(R) and Soltamox(R) With Prime Therapeutics Specialty Pharmacy

Marketwire (Apr 3, 2013)
DARA Reports Year-End 2012 Financial Results

Marketwire (Apr 1, 2013)
DARA BioSciences to Present at 25th Annual ROTH Conference

Marketwire (Mar 18, 2013)
DARA BioSciences Appoints Haywood Cochrane Jr. as Chairman of the Board of Directors and Names Paul Richardson as a New Board Member

Marketwire (Mar 1, 2013)
DARA BioSciences Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule

Business Wire (Feb 14, 2013)
DARA BioSciences to Present at 15th Annual BIO CEO & Investor Conference

Business Wire (Feb 11, 2013)
DARA BioSciences to Present at the 6th Annual OneMedForum Conference

Business Wire (Jan 8, 2013)
DARA BioSciences to Raise $2.8 Million Pursuant to Securities Purchase Agreement

Business Wire (Dec 31, 2012)
DARA BioSciences Announces Submission of KRN5500 to FDA for Orphan Designation

Business Wire (Nov 29, 2012)
DARA BioSciences Reports Financial Results for the Third Quarter 2012

Business Wire (Nov 14, 2012)
DARA BioSciences Will Present at NYSSA Investing in Life Sciences Conference, November 29

Business Wire (Nov 12, 2012)
DARA BioSciences Will Present at Singular Research Conference November 1

Business Wire (Oct 29, 2012)
DARA BioSciences Announces the U.S. Launch of Soltamox®

Business Wire (Oct 22, 2012)
DARA BioSciences Launches Soltamox®, First and Only Liquid Version of Tamoxifen Citrate

Business Wire (Oct 22, 2012)
DARA BioSciences Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule

Business Wire (Oct 2, 2012)
DARA BioSciences Establishes Vertically Integrated Commercial Platform for Specialty Oncology Care and Support Products

Business Wire (Sep 25, 2012)
Helsinn Grants to DARA Exclusive U.S. Commercial Rights to Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis

Business Wire (Sep 13, 2012)
DARA BioSciences Names Timothy Heady, Former CEO of UnitedHealthcare Pharmacy, to its Board

Business Wire (Aug 21, 2012)

DARA vs. ETF Alternatives

Company Description

Currently, there's no company description for DARA.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 2:30 PM Dara Biosciences (DARA -3%) slips after its Q1 EPS missed estimates yesterday. Bottom line results were negatively impacted by costs incurred in the establishment of a sales and marketing, distribution and regulatory infrastructure to support the promotion of its oncology and oncology supportive care products. Comment! [Healthcare, Earnings, On the Move]
Wednesday, May 15, 4:59 PM Dara BioSciences (DARA): Q1 EPS of -$0.11 misses by $0.04. Revenue of $21.2K. Shares +2.7% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Wednesday, April 3, 8:56 AM Dara BioSciences (DARA +4.1%) signs an agreement with pharmacy benefit manager Prime Therapeutics for the latter to distribute Dara's Gelclair bioadhesive pain-relieving gel for patients with oral mucositis (OOM) and its Soltamox oral solution for breast-cancer patients. OM is inflammation and ulceration in the mouth and is common in patients undergoing chemotherapy and radiotherapy. (PR) Comment! [Healthcare, On the Move]
Friday, March 1, 2:21 PM DARA Biosciences (DARA -1.1%) says it's appointed Haywood D. Cochrane Jr. as chairman of the board of directors and Paul Richardson as a new board member. Mr. Cochrane has served as a member of DARA's board since February 2008 and has over 30 years of healthcare experience. Mr. Richardson had previously served on the board of a public company specializing in oncology supportive care. Comment! [Healthcare, On the Move]
Monday, December 31, 2012, 12:26 PM Dara BioSciences (DARA -3.3%) dips after saying it's has entered into a $2.8M securities purchase agreement with some select investors for mix of convertible preferred stock and warrants. None of the warrants are exercisable for six months from the initial issuance date, and the convertible preferred stock is convertible at any time into shares of common stock at an initial conversion price of $0.76 per share. Comment! [Healthcare, On the Move]
Tuesday, October 2, 2012, 10:29 AM Dara BioSciences (DARA +3%) moves up after saying that Nasdaq notified the company that it has regained compliance with Rule 5550(a)(2), which requires a minimum bid price of $1.00 for continued listing. The company added that a special meeting of stockholders that was scheduled on November 8 to consider a reverse stock split proposal to deal with the issue has been canceled as a result. 1 Comment [Healthcare, On the Move]
Tuesday, September 25, 2012, 11:15 AM Dara BioSciences (DARA +5.5%) pops after the company announced the completion of a series of agreements with a number of specialty pharmacy providers, leading group purchasing organizations, retail partners, reimbursement experts, and a third-party logistics provider, which should significantly enhance its commercial scale and capabilities. Its distribution network now consists of more than 45K retail pharmacies, mail order pharmacies, and long-term care facilities. Comment! [Healthcare, On the Move]
Tuesday, September 25, 2012, 9:10 AM Premarket gainers: GENE +14%. DARA +13%. PPHM +8%. ATRS +8%. PURE +6%. UDRL +6%. ROSG +6%.
Losers: GEVO -16%. TSLA -8%. KEG -8%. Comment! [On the Move]
Friday, September 14, 2012, 1:57 PM Dara Biosciences (DARA +20.7%) regains yesterday's upward move plus more after saying it's signed an exclusive agreement with The Helsinn Group of Switzerland for the U.S. commercial rights to Gelclair. Gelclair is an FDA-cleared topical gel topical gel used to reduce pain from oral mucositis. Comment! [Healthcare, On the Move]
Thursday, August 16, 2012, 10:41 AM DARA BioSciences (DARA -1.5%) enters into an exclusive distribution agreement with Seyer Pharmatec for the sale and distribution of Soltamox in the Commonwealth of Puerto Rico. The company plans to launch Soltamox later this year. Comment! [Healthcare]
Monday, May 21, 2012, 11:24 AM Dara Biosciences (DARA -2.3%)) slips after reporting a Q1 net loss of $2M, or $0.29 cents per share, compared to a net loss of $1.3M, or $0.26 cents per share in the same period last year. The higher net loss was due primarily to business acquisition costs and the hiring of experienced staff to help execute its new oncology-focused business strategy. Comment! [Healthcare, Earnings]
Wednesday, February 15, 2012, 12:01 PM DARA Biosciences (DARA +8.5%) pops after signing an exclusive agreement with Uman Pharma for U.S. commercialization rights to its newly licensed anticancer-agent gemcitabine. Comment! [Healthcare, On the Move]
Thursday, August 18, 2011, 2:33 PM Shares in DARA BioSciences (DARA +8.7%) get a boost today, after commenting earlier that its investigational drug KRN5500 has been granted a fast-track designation by the FDA to treat chemotherapy-induced neuropathic pain in cancer patients. Comment! [Healthcare, On the Move]

sling
It appears that a nice amount of inside buying has taken place on 3/4/13. Go $DARA, it's a steal under $1.00.
Mar 5, 8:42 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

BBKing20013
$DARA headed to two dollars!
Feb 18, 12:25 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chemistfrog
$ACRX looks to be consolidating for the next leg up. Before or after 1Q data release? $DARA with many imminent catalysts
Feb 5, 5:36 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Napodano: DARA Bio Looking For A Turnaround $DARA $SPY $IWM $QQQ $DIA $$ http://bit.ly/I3MbJP
4/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Biotech: DARA Focuses On Oncology: The Right Move $DARA $QQQ $$ #Biotech #KSMT http://bit.ly/AAcOTY
3/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

DARA DARA Biosciences, Inc.

DARA

DARA Biosciences, Inc.